Innovative Rectal Suspension of Mesalamine Utilizing Mesoporous Silica for Sustained and Colon-Specific Drug Delivery Novel rectal suspension of mesalamine
Iranian Journal of Pharmaceutical Sciences,
Vol. 21 No. 1 (2025),
21 Bahman 2025
,
Page 382-389
https://doi.org/10.22037/ijps.v21i1.47482
Abstract
Mesalamine is an anti-inflammatory drug for the treatment of ulcerative colitis-related colon cancer. The present study aims to evaluate the rectal suspension of mesoporous mesalamine for improved localized effect of the drug in the ulcerative colon of rodents. Syloid 244FP and Syloid XDP were employed to form a solid dispersion of mesalamine using the solvent evaporation technique, with a drug-to-carrier ratio of 1:1. The formulations were evaluated for drug loading, and an in vitro drug release study was conducted over 8 hours. The drug and excipients were subjected to studies on incompatibility, surface characteristics, and surface morphology. A reconstitutable suspension (9% w/w) was prepared using carbomer 934 and Xanthum gum as suspending agents. Ulceration was induced in the animals, and the effect of the formulations on the ulcerative colon was observed through a histopathological study. The FTIR study revealed the compatibility between the drug and the carriers, while surface morphology and surface characteristics studies revealed the amorphization of the drug. Syloid 244FP was found to be the best carrier in terms of loading mesalamine and releasing the drug in a sustained manner for 8 hours. The histopathological study revealed that prolonged localization of the drug could provide significant healing in the ulcerative colons of the animals. Therefore, it can be concluded that the sustained release solid dispersion of mesalamine in mesoporous silica could enhance the local activity of mesalamine in the treatment of ulcerative colitis.
- Mesalamine
- Rectal suspension
- Mesoporous silica
- Solid dispersion
How to Cite
References
Yanes RE, Lu J, Tamanoi F. Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy. 1st ed. Vol. 32, Enzymes. Elsevier Inc.; 2012. 185–203.
Mitran RA, Deaconu M, Matei C, Berger D. Mesoporous Silica as Carrier for Drug-Delivery Systems. Nanocarriers for Drug Delivery. Elsevier Inc.; 2019. 351–374.
Le TT, Elyafi AKE, Mohammed AR, Al-Khattawi A. Delivery of poorly soluble drugs via mesoporous silica: Impact of drug overloading on release and thermal profiles. Pharmaceutics (2019) 11(6):269.
Bremmell KE, Prestidge CA. Enhancing oral bioavailability of poorly soluble drugs with mesoporous silica-based systems: opportunities and challenges. Drug Dev. Ind. Pharm (2019) 45(3):349–58.
Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today (2007) 12(23–24):1068–75.
Tran PHL, Tran TTD. Dosage form designs for the controlled drug release of solid dispersions. Int. J. Pharm (2020) 581:119274.
Pednekar PP, Godiyal SC, Jadhav KR, Kadam VJ. Mesoporous silica nanoparticles: A promising multifunctional drug delivery system. Nanostructures for Cancer Therapy. Elsevier Inc.; 2017. 593–621.
Mesalamine Monograph for Professionals. https://www.drugs.com/monograph/mesalamine.html (Accessed Jan 2, 2025)
Bayan MF, Bayan RF. Recent advances in mesalamine colonic delivery systems. Futur J. Pharm. Sci. (2020) 6(1),43.
Seifirad S, Karami H, Shahsavari S, Mirabasi F, Dorkoosh F. Design and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System. Nanomedicine Res. J. (2016) 1(2): 97-106.
Dening TJ, Taylor LS. Supersaturation Potential of Ordered Mesoporous Silica Delivery Systems. Part 1: Dissolution Performance and Drug Membrane Transport Rates. Mol. Pharm (2018) 15(8):3489–501.
Shah H, Shah V, Bhutani S, Parikh D, Mehta T. Dissolution improvement of nebivolol hydrochloride using solid dispersion adsorbate technique. Asian J. Pharm (2015) 9(1): 49–55.
Bhattacharyya S, Adhikari H, Regmi D, Reddy RHV. A Study on Solubility Enhancement of Etravirine by Crystal Engineering Method. Indian J. Pharm. Sci. (2020) 84(3):575-585.
FDA dissolution method, https://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults.cfm (Accessed June 5, 2024)
Sujitha V, Bhattacharyya S, Geetha T. Preparation and evaluation of orally disintegrating taste masking tablet of paracetamol with Kollicoat Smart Seal 30 D. Der. Pharm. Lett. (2014) 6(2):82–9.
Sawarkar SP, Deshpande SG, Bajaj AN, Nikam VS. In Vivo Evaluation of 5-ASA Colon-Specific Tablets Using Experimental-Induced Colitis Rat Animal Model. AAPS PharmSci. Tech (2015) 16(6):1445–54.
Fernandes RI, Bhattacharyya S. Preparation and evaluation of mesoporous Celecoxib for improved antiarthritic activity in rodents. Thai J Pharm Sci (2025) 49(1):e5.
Xueting G, Yibin G, Maolian Z, Bing Y, Hao L, Tian Y, et al A comparative study on in vitro and in vivo characteristics of enzalutamide nanocrystals versus amorphous solid dispersions and a better prediction for bioavailability based on “spring-parachute” model. Int J. Pharm (2022) 628:12233.
Anandhu M, Madhappan S, Young-Chul L. Recent advances in the pH-responsive organic–inorganic mesoporous hybrid silica for targeted drug delivery. Eur. Polym. J. (2024) 206:112783.
Trzeciak K, Chotera-Ouda A, Bak-Sypien II, Potrzebowski MJ. Mesoporous Silica Particles as Drug Delivery Systems-The State of the Art in Loading Methods and the Recent Progress in Analytical Techniques for Monitoring These Processes. Pharmaceutics (2021) 13(7):950.
- Abstract Viewed: 258 times
- IJPS_Volume21_Issue1_Pages382-389 Downloaded: 158 times